Posted by Michael Wonder on 14 Oct 2016
Bristol-Myers Squibb receives positive CHMP opinion for Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin
14 October 2016 - CHMP decision based on overall response rate demonstrated by data from two trials, CheckMate -205 and CheckMate -039.
Bristol-Myers Squibb Company today announced the CHMP of the EMA has recommended the approval of Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.
The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.
